^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Ocular Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Hindawi
    Title:

    Systemic Treatment of Metastatic Conjunctival Melanoma

    Published date:
    10/26/2017
    Excerpt:
    A mutation in exon 15 of the BRAF gene (V600) was detected by Cobas 4800….In April 2014, systemic therapy was initiated with vemurafenib (960 mg) twice a day….After one month of therapy, there was full symptomatic resolution….Recent reevaluation showing sustained complete response to vemurafenib, 34 months after starting the treatment...
    DOI:
    https://doi.org/10.1155/2017/4623964
    Test:
    cobas® 4800 BRAF V600 Mutation Test